About Vuja De Sciences
Vuja De Sciences is a Healthcare company based in Hoboken (United States) founded in 2017. It operates as a therapies for preventing cancer metastasis and recurrence are developed. Vuja De Sciences has raised $3.94 million across 10 funding rounds. Vuja De Sciences offers products and services including Discovery Platform. Its focus areas include Life Sciences, Oncology, Drugs and Bone Cancer. Its legal entity is Vuja De Sciences, Inc. Its competitors include SpringWorks Therapeutics, QSAM Biosciences, ECM Therapeutics, Taithera and Atlanthera and 3 more; 3 of its 8 listed competitors have raised funding.
Company details
Vuja De Sciences was founded in 2017 and is based in Hoboken, United States. Focus is placed on the biotechnology sector, specifically oncology, where therapies aimed at preventing cancer metastasis and recurrence are developed. A lead candidate, VUJ-100, is advanced using a proprietary platform that demonstrates anti-metastatic activity across models, including metastatic osteosarcoma and other cancers. Operations involve research and development for these therapeutic applications.
- Headquarters Hoboken, United States
- SectorsHealthcare
- Email••••••••
- Website vujade-life.com
- Legal Name Vuja De Sciences, Inc.
- Total Equity Funding$3.94M (USD)
in 10 rounds
- Latest Funding Round$370K (USD), Seed
Oct 2024
Products & Services of Vuja De Sciences
Vuja De Sciences offers a comprehensive portfolio of products and services, including Discovery Platform.
Platform identifies drugs targeting metastatic endurance in tumors.
Funding Insights of Vuja De Sciences
Vuja De Sciences has successfully raised a total of $3.94M across 10 strategic funding rounds. The most recent funding activity was a Seed round of $370 thousand completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.94M
- Total Rounds 10
- Last Round Seed — $370,000
- First Round $501,340
(May 2019)
All 10 funding rounds of Vuja De Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $370,000 | Seed | – | – | – |
| Oct 2024 | – | Debt – Conventional | – | – | – |
| Feb 2024 | $700,000 | Seed | – | – | – |
| Feb 2024 | – | Debt – Conventional | – | – | – |
| Oct 2023 | $391,060 | Seed | – | – | – |
| Nov 2022 | $875,000 | Seed | – | – | – |
| Nov 2022 | – | Debt – Conventional | – | – | – |
| May 2021 | $1.22M | Seed | – | – | – |
| May 2020 | $387,000 | Seed | – | – | – |
| May 2019 | $501,340 | Debt – Conventional | – | – | – |
People of Vuja De Sciences
12 people are tracked at Vuja De Sciences (1 in leadership, 10 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Robert E. Hurst | Co-Founder & Chief Scientific Officer | Leadership |
Mike Ihnat | Advisor | Board & advisors |
Dalit Barkan | Advisor | Board & advisors |
Aykut Uren | Advisor | Board & advisors |
Gil Ben Menachem | Advisor | Board & advisors |
Rafael Torgovicky | Advisor | Board & advisors |
George Sledge | Advisor | Board & advisors |
Chand Khanna | Director | Board & advisors |
Lee Helman | Director | Board & advisors |
Peter C. Scacheri | Advisor | Board & advisors |
Carl Barrett | Director | Board & advisors |
Ofir Barkan | Business Development Manager | Team |
Complete people profiles for Vuja De Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vuja De Sciences
3 dated milestones of Vuja De Sciences across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Vuja De Sciences is founded.
- Funding First funding round of $501K.
- Funding Latest funding round, Seed, of $370K.
Competitors of Vuja De Sciences
Vuja De Sciences has 8 listed competitors in our database, 3 of them funded. They include SpringWorks Therapeutics, QSAM Biosciences, ECM Therapeutics, Taithera and Atlanthera, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| springworkstx.com | 2017 | New York, United States | $229.6M | 305 | Small molecule therapeutics are developed for cancer and rare diseases. | |
| qsambio.com | 2004 | Palm Beach, United States | – | 4 | Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation | |
| ecmtherapeutics.com | 2018 | Warrendale, United States | $26.1M | – | Diagnostic and therapeutic products from extracellular matrix are developed. | |
| taithera.com | 2016 | New York, United States | – | – | Nanomedicine platform for targeted bone drug delivery is developed. | |
| atlanthera.com | 2010 | Saint Herblain, France | $1.11M | – | Small molecule drugs for bone diseases and tumors are developed. | |
| flashthera.com | 2019 | Yokohama, Japan | – | – | Novel therapeutics are developed to treat acute myeloid leukemia. | |
| cartilago.it | 2018 | Maglie, Italy | – | – | Molecular technology for regenerative medicine is developed by Cartilago. | |
| aptadeltx.com | 2020 | Barcelona, Spain | – | – | Develops RNA Aptamer technologies for targeted cancer drug delivery. |
Detailed competitors of Vuja De Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Vuja De Sciences (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vuja De Sciences
Complete news archive for Vuja De Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vuja De Sciences
Vuja De Sciences was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Vuja De Sciences is headquartered in Hoboken, United States. It is registered at Hoboken, New Jersey, United States.
Vuja De Sciences is a funded company, having raised a total of $3.94M across 10 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $501.34K, raised on May 2019.
Vuja De Sciences was founded in 2017 and is based in Hoboken, United States. Focus is placed on the biotechnology sector, specifically oncology, where therapies aimed at preventing cancer metastasis and recurrence are developed. A lead candidate, VUJ-100, is advanced using a proprietary platform that demonstrates anti-metastatic activity across models, including metastatic osteosarcoma and other cancers. Operations involve research and development for these therapeutic applications.
Vuja De Sciences's top competitors include SpringWorks Therapeutics, QSAM Biosciences and Taithera.
Vuja De Sciences offers Discovery Platform.
Vuja De Sciences operates through Vuja De Sciences, Inc..